These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

685 related items for PubMed ID: 20374353

  • 1. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    Wanchu A, Suryanaryana BS, Sharma S, Sharma A, Bambery P.
    Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
    Bérezné A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J, Cohen P, Mahr A, Pagnoux C, Hachulla E, Kahan A, Cabane J, Guillevin L, Mouthon L.
    J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM.
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [Abstract] [Full Text] [Related]

  • 4. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y, Kuwana M.
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [Abstract] [Full Text] [Related]

  • 5. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L.
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [Abstract] [Full Text] [Related]

  • 6. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT, Simons SO, Teesselink E, Knaapen-Hans HKA, van den Hoogen FHJ, Fransen J, Vonk MC.
    Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
    [Abstract] [Full Text] [Related]

  • 7. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
    Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, Valentini G.
    Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.
    Espinosa G, Simeón CP, Plasín MÁ, Xaubet A, Muñoz X, Fonollosa V, Cervera R, Vilardell M.
    Arch Bronconeumol; 2011 May; 47(5):239-45. PubMed ID: 21458128
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis.
    Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, Celik I.
    Clin Rheumatol; 2003 Oct; 22(4-5):289-94. PubMed ID: 14579158
    [Abstract] [Full Text] [Related]

  • 10. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
    Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L.
    Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
    [Abstract] [Full Text] [Related]

  • 11. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
    Várai G, Earle L, Jimenez SA, Steiner RM, Varga J.
    J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
    [Abstract] [Full Text] [Related]

  • 12. Cyclophosphamide versus placebo in scleroderma lung disease.
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group.
    N Engl J Med; 2006 Jun 22; 354(25):2655-66. PubMed ID: 16790698
    [Abstract] [Full Text] [Related]

  • 13. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
    Balbir-Gurman A, Yigla M, Guralnik L, Hardak E, Solomonov A, Rozin AP, Toledano K, Dagan A, Bishara R, Markovits D, Nahir MA, Braun-Moscovici Y.
    Isr Med Assoc J; 2015 Mar 22; 17(3):150-6. PubMed ID: 25946765
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up.
    Tochimoto A, Kawaguchi Y, Hara M, Tateishi M, Fukasawa C, Takagi K, Nishimagi E, Ota Y, Katsumata Y, Gono T, Tanaka E, Yamanaka H.
    Mod Rheumatol; 2011 Jun 22; 21(3):296-301. PubMed ID: 21240620
    [Abstract] [Full Text] [Related]

  • 15. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP, Scleroderma Lung Study Group.
    Arthritis Rheum; 2005 Feb 22; 52(2):592-600. PubMed ID: 15692967
    [Abstract] [Full Text] [Related]

  • 16. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.
    Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C.
    J Rheumatol; 1993 May 22; 20(5):838-44. PubMed ID: 8336309
    [Abstract] [Full Text] [Related]

  • 17. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.
    Airò P, Danieli E, Rossi M, Frassi M, Cavazzana I, Scarsi M, Grottolo A, Franceschini F, Zambruni A.
    Clin Exp Rheumatol; 2007 May 22; 25(2):293-6. PubMed ID: 17543156
    [Abstract] [Full Text] [Related]

  • 18. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
    Colaci M, Sebastiani M, Giuggioli D, Manfredi A, Spagnolo P, Luppi F, Richeldi L, Ferri C.
    Scand J Rheumatol; 2010 Mar 22; 39(2):155-9. PubMed ID: 20059446
    [Abstract] [Full Text] [Related]

  • 19. Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.
    Tzelepis GE, Plastiras SC, Karadimitrakis SP, Vlachoyiannopoulos PG.
    Clin Exp Rheumatol; 2007 Mar 22; 25(5):734-9. PubMed ID: 18078622
    [Abstract] [Full Text] [Related]

  • 20. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
    Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG.
    J Rheumatol; 2002 Feb 22; 29(2):298-304. PubMed ID: 11842824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.